The purpose of this study is to determine whether prostacyclin is effective in prevention of cerebral vasospasm in patients with subarachnoidal hemorrhage (SAH).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
90
Continuous i.v. infusion of epoprostenol 1 ng/kg/min day 5-10 after SAH
Continuous i.v. infusion of epoprostenol 2 ng/kg/min day 5-10 after SAH
Continuous i.v. infusion with placebo day 5-10 after SAH
Rigshospitalet, dep. of neurosurgery
Copenhagen, Denmark
Radiographic vasospasm measured by CT perfusion
Changes in regional cerebral blood flow from baseline in the arterial territories of the anterior cerebral artery, medial cerebral artery and the posterior cerebral artery
Time frame: Day 8 (+/- 1 day) after aneurysm treatment
Cerebral metabolism measured by microdialysis
Cerebral metabolism measured by microdialysis. Lactate, pyruvate, glucose, glutamate and glycerol are measured.
Time frame: every 2. hour day 3-10 after aneurysm treatment
Glasgow outcome scale (GOS) at 3 months
Glasgow outcome scale (GOS) at 3 months obtained by telephone interview.
Time frame: 3 months efter SAH
Clinical vasospasm
Clinical vasospasm defined as delayed neurological deficits (DIND).
Time frame: day 5-10 after SAH
Brain tissue oxygen (PtiO2)
Brain tissue oxygen (PtiO2) measured by Licox catheter.
Time frame: continuous measurement day 3-10 after SAH
Mean arterial pressure (MAP)
Mean arterial pressure (MAP) measured by arterial catheter.
Time frame: Continuous day 1-10 after SAH
Radiographic vasospasm measured by CT angiography
Qualitative assessment (none, mild/moderate, severe) of vasospasm.
Time frame: Measured day 8 +/- 1 day
Level of brain damage biomarker
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Serum levels of S100b in peripheral blood
Time frame: daily day 4-11 after SAH